Anna M. Gutridge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna M. Gutridge has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Richard M. van Rijn
Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States
4 shared publications - Andrew P. Riley
University of Illinois Chicago
2 shared publications - Elizabeth S. Rhoda
Purdue University West Lafayette
2 shared publications - Yazan J. Meqbil
Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States
2 shared publications - Alexander R. French
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, United States
1 shared publication Angel Lin
1 shared publication
Latest Publications
- Open Access
- 29 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Discovery of Potent Kappa Opioid Receptor Agonists Derived from Akuammicine
Akuammicine (1), an indole alkaloid isolated from the seeds of Picralima nitida, is a selective agonist of the kappa opioid receptor (κOR). To establish structure-activity relationships (SAR) for this structurally unique κOR ligand, a collection of 26 semisynthetic derivatives of 1 were synthesized. Evaluating these derivatives for their ability to activate the κOR and mu opioid receptor (µOR) revealed key SAR trends and identified derivatives with enhanced κOR potency. Most notably, substitutions to the C10 position of the aryl ring led to a >200-fold improvement in κOR potency and nearly complete selectivity for the κOR over other CNS receptor targets. Activation of the κOR by these analogues also results in the recruitment of β-Arrestin-2, indicating they are balanced agonists and have distinct signaling properties from other recently identified κOR agonists. The discovery of these κOR agonists underscores the potential of using natural products to identify new classes of highly potent and selective ligands and provides new pharmacology tools to probe the κOR.
- 29 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDiscovery of Potent Kappa Opioid Receptor Agonists Derived from Akuammicine
Akuammicine (1), an indole alkaloid isolated from the seeds of Picralima nitida, is a selective agonist of the kappa opioid receptor (κOR). To establish structure-activity relationships (SAR) for this structurally unique κOR ligand, a collection of 26 semisynthetic derivatives of 1 were synthesized. Evaluating these derivatives for their ability to activate the κOR and mu opioid receptor (µOR) revealed key SAR trends and identified derivatives with enhanced κOR potency. Most notably, substitutions to the C10 position of the aryl ring led to a >200-fold improvement in κOR potency and nearly complete selectivity for the κOR over other CNS receptor targets. Activation of the κOR by these analogues also results in the recruitment of β-Arrestin-2, indicating they are balanced agonists and have distinct signaling properties from other recently identified κOR agonists. The discovery of these κOR agonists underscores the potential of using natural products to identify new classes of highly potent and selective ligands and provides new pharmacology tools to probe the κOR.
- Open Access
- 8 February 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Modified Akuamma Alkaloids with Increased Potency at the Mu-opioid Receptor
Akuammine (1) and pseudo-akuammigine (2) are indole alkaloids found in the seeds of the akuamma tree (Picralima nitida). Both alkaloids are weak agonists of the mu opioid receptor (µOR); however, they produce minimal effects in animal models of antinociception. To probe the interactions of 1 and 2 at the opioid receptors, we have prepared a collection of 22 semi-synthetic derivatives. Evaluation of this collection at the µOR and kappa opioid receptor (κOR) revealed structural-activity relationship trends and derivatives with improved potency at the OR. Most notably, the introduction of a phenethyl moiety to the N1 of 2 produces a 70-fold increase in potency and a 7-fold increase in selectivity for the µOR. The in vitro potency of this compound resulted in increased efficacy in the tail-flick and hot-plate assays of antinociception. The improved potency of these derivatives highlights the promise of exploring natural product scaffolds to probe the opioid receptors.
- 8 February 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessModified Akuamma Alkaloids with Increased Potency at the Mu-opioid Receptor
Akuammine (1) and pseudo-akuammigine (2) are indole alkaloids found in the seeds of the akuamma tree (Picralima nitida). Both alkaloids are weak agonists of the mu opioid receptor (µOR); however, they produce minimal effects in animal models of antinociception. To probe the interactions of 1 and 2 at the opioid receptors, we have prepared a collection of 22 semi-synthetic derivatives. Evaluation of this collection at the µOR and kappa opioid receptor (κOR) revealed structural-activity relationship trends and derivatives with improved potency at the OR. Most notably, the introduction of a phenethyl moiety to the N1 of 2 produces a 70-fold increase in potency and a 7-fold increase in selectivity for the µOR. The in vitro potency of this compound resulted in increased efficacy in the tail-flick and hot-plate assays of antinociception. The improved potency of these derivatives highlights the promise of exploring natural product scaffolds to probe the opioid receptors.
- Open Access
Identification of a Novel Delta Opioid Receptor Agonist Chemotype with Potential Negative Allosteric Modulator Capabilities
The δ-opioid receptor (δOR) holds great potential as a therapeutic target. Yet, clinical drug development, which has focused on δOR agonists that mimic the potent and selective tool compound SNC80 have largely failed. It has increasingly become apparent that the SNC80 scaffold carries with it potent and efficacious β-arrestin recruitment. Here, we screened a relatively small (5120 molecules) physical drug library to identify δOR agonists that underrecruit β-arrestin, as it has been suggested that compounds that efficaciously recruit β-arrestin are proconvulsant. The screen identified a hit compound and further characterization using cellular binding and signaling assays revealed that this molecule (R995045, compound 1) exhibited ten-fold selectivity over µ- and κ-opioid receptors. Compound 1 represents a novel chemotype at the δOR. A subsequent characterization of fourteen analogs of compound 1, however did not identify a more potent δOR agonist. Computational modeling and in vitro characterization of compound 1 in the presence of the endogenous agonist leu-enkephalin suggest compound 1 may also bind allosterically and negatively modulate the potency of Leu-enkephalin to inhibit cAMP, acting as a ‘NAM-agonist’ in this assay. The potential physiological utility of such a class of compounds will need to be assessed in future in vivo assays.
Open AccessIdentification of a Novel Delta Opioid Receptor Agonist Chemotype with Potential Negative Allosteric Modulator Capabilities
The δ-opioid receptor (δOR) holds great potential as a therapeutic target. Yet, clinical drug development, which has focused on δOR agonists that mimic the potent and selective tool compound SNC80 have largely failed. It has increasingly become apparent that the SNC80 scaffold carries with it potent and efficacious β-arrestin recruitment. Here, we screened a relatively small (5120 molecules) physical drug library to identify δOR agonists that underrecruit β-arrestin, as it has been suggested that compounds that efficaciously recruit β-arrestin are proconvulsant. The screen identified a hit compound and further characterization using cellular binding and signaling assays revealed that this molecule (R995045, compound 1) exhibited ten-fold selectivity over µ- and κ-opioid receptors. Compound 1 represents a novel chemotype at the δOR. A subsequent characterization of fourteen analogs of compound 1, however did not identify a more potent δOR agonist. Computational modeling and in vitro characterization of compound 1 in the presence of the endogenous agonist leu-enkephalin suggest compound 1 may also bind allosterically and negatively modulate the potency of Leu-enkephalin to inhibit cAMP, acting as a ‘NAM-agonist’ in this assay. The potential physiological utility of such a class of compounds will need to be assessed in future in vivo assays.
- Open Access
β-arrestin-dependent ERK signaling positively correlates with reduced anxiety-like and conditioned fear-related behavior in mice
Exposure to anxiety- or fear-invoking stimuli initiates a convergence of executive actions orchestrated by multiple proteins and neurotransmitters across the brain. Dozens of G protein-coupled receptors (GPCRs) have been linked to regulation of fear and anxiety. GPCR signaling involves canonical G protein pathways but may also engage downstream kinases and effectors through β-arrestin scaffolds. Here, we investigate whether β-arrestin signaling can regulate anxiety-like and fear-related behavior. Using the δ-opioid receptor (δOR) as a model GPCR, we found that β-arrestin 2-dependent activation of extracellular signal–regulated kinases (ERK1/2) in the dorsal hippocampus and the amygdala are critical for δOR agonist-induced anxiolytic-like effects. In contrast, G protein-mediated δOR signaling was associated with decreased ERK1/2 activity and increased fear-related behavior. Our results also indicate unique contributions for β-arrestin isoforms in modulation of anxiety-like and fear-related behavior. Overall, our findings highlight the significance of non-canonical β-arrestin signaling in the regulation of emotions. One sentence summary: Using pharmacological and genetic strategies, we reveal the importance of non-canonical β-arrestin-mediated G protein-coupled receptor signaling in anxiety-like behaviors.
Open Accessβ-arrestin-dependent ERK signaling positively correlates with reduced anxiety-like and conditioned fear-related behavior in mice
Exposure to anxiety- or fear-invoking stimuli initiates a convergence of executive actions orchestrated by multiple proteins and neurotransmitters across the brain. Dozens of G protein-coupled receptors (GPCRs) have been linked to regulation of fear and anxiety. GPCR signaling involves canonical G protein pathways but may also engage downstream kinases and effectors through β-arrestin scaffolds. Here, we investigate whether β-arrestin signaling can regulate anxiety-like and fear-related behavior. Using the δ-opioid receptor (δOR) as a model GPCR, we found that β-arrestin 2-dependent activation of extracellular signal–regulated kinases (ERK1/2) in the dorsal hippocampus and the amygdala are critical for δOR agonist-induced anxiolytic-like effects. In contrast, G protein-mediated δOR signaling was associated with decreased ERK1/2 activity and increased fear-related behavior. Our results also indicate unique contributions for β-arrestin isoforms in modulation of anxiety-like and fear-related behavior. Overall, our findings highlight the significance of non-canonical β-arrestin signaling in the regulation of emotions. One sentence summary: Using pharmacological and genetic strategies, we reveal the importance of non-canonical β-arrestin-mediated G protein-coupled receptor signaling in anxiety-like behaviors.